AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Acceleron PharmaSpark TherapeuticsChina Biologic ProductsAblynxIovance Biotherapeutics
SymbolNASDAQ:XLRNNASDAQ:ONCENASDAQ:CBPOOTCMKTS:ABLYFNASDAQ:IOVA
Price Information
Current Price$92.09$113.57$109.94$50.63$30.86
52 Week RangeBuyHoldN/AN/ABuy
Beat the Market™ Rank
Overall Score1.51.10.70.41.7
Analysis Score3.41.00.00.04.5
Community Score2.92.72.22.23.2
Dividend Score0.00.00.00.00.0
Ownership Score1.01.00.00.01.0
Earnings & Valuation Score0.00.61.30.00.0
Analyst Ratings
Consensus RecommendationBuyHoldN/AN/ABuy
Consensus Price Target$111.92$114.50N/AN/A$43.31
% Upside from Price Target21.54% upside0.82% upsideN/AN/A40.34% upside
Trade Information
Market Cap$5.00 billion$4.37 billion$4.33 billion$3.81 billion$4.07 billion
Beta0.772.050.821.991.17
Average Volume606,603419,933110,667N/A1,961,843
Sales & Book Value
Annual Revenue$73.99 million$64.72 million$503.70 million$62.73 millionN/A
Price / Sales66.9967.598.5960.74N/A
CashflowN/AN/A$4.94 per shareN/AN/A
Price / CashN/AN/A22.25N/AN/A
Book Value$8.47 per share$13.15 per share$45.09 per share$2.71 per share$2.37 per share
Price / Book10.878.642.4418.68N/A
Profitability
Net Income$-124,860,000.00$-78,820,000.00$138.81 million$-122,670,000.00$-197,560,000.00
EPS($2.38)($2.11)$4.28N/A($1.59)
Trailing P/E RatioN/AN/A27.830.00N/A
Forward P/E RatioN/AN/A24.54N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-182.31%-358.41%28.80%N/AN/A
Return on Equity (ROE)-30.14%-59.10%10.01%N/A-71.12%
Return on Assets (ROA)-27.01%-33.13%9.16%N/A-62.87%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.04%0.35%N/AN/A0.01%
Current Ratio15.15%4.67%10.51%N/A6.48%
Quick Ratio15.15%4.35%8.86%N/A6.48%
Ownership Information
Institutional Ownership Percentage88.46%88.37%29.13%N/A95.98%
Insider Ownership Percentage2.50%6.00%2.73%N/A9.30%
Miscellaneous
Employees1733682,269N/A88
Shares Outstanding53.83 million38.52 million39.36 million75.25 million126.86 million
Next Earnings Date8/3/2020 (Estimated)N/A8/3/2020 (Estimated)N/A8/6/2020 (Estimated)
OptionableOptionableOptionableOptionableNot OptionableOptionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.